The role of gefitinib in the management of Asian patients with non-small cell lung cancer

Research output: Contribution to journalReview article

Abstract

Background: Lung cancer is the most common cause of death in cancer patients worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases. The prognosis of NSCLC is still poor, albeit slow and steady improvement achieved in the past three decades by chemotherapy. Recently, the importance of epidermal growth factor receptor (EGFR) in the pathogenesis and progression in NSCLC was identified particularly in those cancer cells with EGFR mutation and/or increased gene copy number. Gefitinib, an EGFR tyrosine kinase inhibitor, was the first agent approved for treating advanced NSCLC. It has become a popular choice in treating Asian patients after a higher response rate was reported in Japanese patients than in non-Japanese patients in the first Phase II trial. Objective: To evaluate the role of gefitinib in the treatment of Asian patients with NSCLC. Methods: A review of published papers in PubMed and Embase (2000 - 2007) and meeting reports of the American Society of Clinical Oncology and World Conference on Lung Cancer (2000 - 2007) was carried out. Results/conclusions: In general, gefitinib is well tolerated. As the second- or third-line treatment, gefitinib has proven survival benefits in Asian patients with advanced NSCLC, when compared with placebo. It has equivalent efficacy to docetaxel with less toxicity as the second-line therapy. As the first-line therapy, it yielded encouraging results but its final role is pending on the results of the ongoing randomised Phase III trial. Gefitinib should be considered as the treatment if choice for second- or third-line therapy in advanced NSCLC in Asian patients after progression from previous chemotherapy. Its role as the first-line, adjuvant or neoadjuvant therapy remains to be determined.

Original languageEnglish (US)
Pages (from-to)401-411
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume17
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Lung Neoplasms
docetaxel
Therapeutics
Drug Therapy
Neoadjuvant Therapy
Gene Dosage
gefitinib
PubMed
Protein-Tyrosine Kinases
Cause of Death
Neoplasms
Placebos
Mutation
Survival

Keywords

  • Asian patients
  • Gefitinib
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pharmacology

Cite this

The role of gefitinib in the management of Asian patients with non-small cell lung cancer. / Chang, Alex Y.

In: Expert Opinion on Investigational Drugs, Vol. 17, No. 3, 03.2008, p. 401-411.

Research output: Contribution to journalReview article

@article{f0b90c780d6e4553a8fd0bd364f7b61e,
title = "The role of gefitinib in the management of Asian patients with non-small cell lung cancer",
abstract = "Background: Lung cancer is the most common cause of death in cancer patients worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85{\%} of lung cancer cases. The prognosis of NSCLC is still poor, albeit slow and steady improvement achieved in the past three decades by chemotherapy. Recently, the importance of epidermal growth factor receptor (EGFR) in the pathogenesis and progression in NSCLC was identified particularly in those cancer cells with EGFR mutation and/or increased gene copy number. Gefitinib, an EGFR tyrosine kinase inhibitor, was the first agent approved for treating advanced NSCLC. It has become a popular choice in treating Asian patients after a higher response rate was reported in Japanese patients than in non-Japanese patients in the first Phase II trial. Objective: To evaluate the role of gefitinib in the treatment of Asian patients with NSCLC. Methods: A review of published papers in PubMed and Embase (2000 - 2007) and meeting reports of the American Society of Clinical Oncology and World Conference on Lung Cancer (2000 - 2007) was carried out. Results/conclusions: In general, gefitinib is well tolerated. As the second- or third-line treatment, gefitinib has proven survival benefits in Asian patients with advanced NSCLC, when compared with placebo. It has equivalent efficacy to docetaxel with less toxicity as the second-line therapy. As the first-line therapy, it yielded encouraging results but its final role is pending on the results of the ongoing randomised Phase III trial. Gefitinib should be considered as the treatment if choice for second- or third-line therapy in advanced NSCLC in Asian patients after progression from previous chemotherapy. Its role as the first-line, adjuvant or neoadjuvant therapy remains to be determined.",
keywords = "Asian patients, Gefitinib, Non-small cell lung cancer",
author = "Chang, {Alex Y}",
year = "2008",
month = "3",
doi = "10.1517/13543784.17.3.401",
language = "English (US)",
volume = "17",
pages = "401--411",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - The role of gefitinib in the management of Asian patients with non-small cell lung cancer

AU - Chang, Alex Y

PY - 2008/3

Y1 - 2008/3

N2 - Background: Lung cancer is the most common cause of death in cancer patients worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases. The prognosis of NSCLC is still poor, albeit slow and steady improvement achieved in the past three decades by chemotherapy. Recently, the importance of epidermal growth factor receptor (EGFR) in the pathogenesis and progression in NSCLC was identified particularly in those cancer cells with EGFR mutation and/or increased gene copy number. Gefitinib, an EGFR tyrosine kinase inhibitor, was the first agent approved for treating advanced NSCLC. It has become a popular choice in treating Asian patients after a higher response rate was reported in Japanese patients than in non-Japanese patients in the first Phase II trial. Objective: To evaluate the role of gefitinib in the treatment of Asian patients with NSCLC. Methods: A review of published papers in PubMed and Embase (2000 - 2007) and meeting reports of the American Society of Clinical Oncology and World Conference on Lung Cancer (2000 - 2007) was carried out. Results/conclusions: In general, gefitinib is well tolerated. As the second- or third-line treatment, gefitinib has proven survival benefits in Asian patients with advanced NSCLC, when compared with placebo. It has equivalent efficacy to docetaxel with less toxicity as the second-line therapy. As the first-line therapy, it yielded encouraging results but its final role is pending on the results of the ongoing randomised Phase III trial. Gefitinib should be considered as the treatment if choice for second- or third-line therapy in advanced NSCLC in Asian patients after progression from previous chemotherapy. Its role as the first-line, adjuvant or neoadjuvant therapy remains to be determined.

AB - Background: Lung cancer is the most common cause of death in cancer patients worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases. The prognosis of NSCLC is still poor, albeit slow and steady improvement achieved in the past three decades by chemotherapy. Recently, the importance of epidermal growth factor receptor (EGFR) in the pathogenesis and progression in NSCLC was identified particularly in those cancer cells with EGFR mutation and/or increased gene copy number. Gefitinib, an EGFR tyrosine kinase inhibitor, was the first agent approved for treating advanced NSCLC. It has become a popular choice in treating Asian patients after a higher response rate was reported in Japanese patients than in non-Japanese patients in the first Phase II trial. Objective: To evaluate the role of gefitinib in the treatment of Asian patients with NSCLC. Methods: A review of published papers in PubMed and Embase (2000 - 2007) and meeting reports of the American Society of Clinical Oncology and World Conference on Lung Cancer (2000 - 2007) was carried out. Results/conclusions: In general, gefitinib is well tolerated. As the second- or third-line treatment, gefitinib has proven survival benefits in Asian patients with advanced NSCLC, when compared with placebo. It has equivalent efficacy to docetaxel with less toxicity as the second-line therapy. As the first-line therapy, it yielded encouraging results but its final role is pending on the results of the ongoing randomised Phase III trial. Gefitinib should be considered as the treatment if choice for second- or third-line therapy in advanced NSCLC in Asian patients after progression from previous chemotherapy. Its role as the first-line, adjuvant or neoadjuvant therapy remains to be determined.

KW - Asian patients

KW - Gefitinib

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=40949147677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949147677&partnerID=8YFLogxK

U2 - 10.1517/13543784.17.3.401

DO - 10.1517/13543784.17.3.401

M3 - Review article

C2 - 18321238

AN - SCOPUS:40949147677

VL - 17

SP - 401

EP - 411

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 3

ER -